Novimmune unit nabs Takeda milestone payment for hemophilia work

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda Pharmaceutical.

The competitive hemophilia A market has seen a lot of intensity in R&D in the past few years, with a focus now on gene therapies. Light Chain Bioscience is focusing its efforts on bispecifics as it hopes to challenge Roche’s bleeding drug Hemlibra, also a bispecific that works as a factor IXa- and factor X-directed antibody. It’s seen top sales estimates of $5 billion a year at peak.